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Background: Bacterial vaginosis is a common gynecologic infection that has been associated with a variety of
gynecologic and obstetric complications, including pelvic inflammatory disease, postabortal infection and prema-
ture delivery. Recent studies suggest that bacterial vaginosis may increase a woman’s risk for human immuno-
deficiency virus (HIV). We undertook this study to assess whether the prevalence and characteristics of bacterial
vaginosis differed according to HIV status in high-risk US women.
Methods: Prevalence of bacterial vaginosis was assessedby Gram’s stain and clinical criteria for 854 HIV-infected
and 434 HIV-uninfected women enrolled in the HIV Epidemiology Research (HER) Study.Multiple logistic regres-
sion techniques were used to determine whether HIV infection independently predicted bacterial vaginosis.
Results: Almost half (46%) the women had bacterial vaginosis by Gram’s stain. The prevalence of bacterial
vaginosiswas47%intheHIV-positivewomencomparedwith44%intheHIV-negativewomen;thisdifferencewas
not statistically significant(p = 0.36). After adjustmentforothercovariates, HIV-positive women weremorelikely
than HIV-negative women to have bacterial vaginosis (odds ratio (OR) 1.31; 95% confidence interval (CI)
1.01–1.70) by Gram’sstain butnot by clinical criteria(OR1.16; CI 0.87–1.55). Among HIV-positivewomen,useof
antiretroviral drugs was associated with a lower prevalence of bacterial vaginosis (adjusted OR 0.54; Cl
0.38 – 0.77).
Conclusions: In this cross-sectional analysis of high-risk US women, HIV infection was positively correlated with
bacterial vaginosis diagnosed by Gram’s stain.
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Clinical study 133Bacterial vaginosis, one of the most common
gynecologic infections in women of reproductive
age, has been associated with such important
problems as premature delivery1-4, endometritis
and pelvic inflammatory disease5-7. In addition,
bacterial vaginosis has been associated with
increased risk of human immunodeficiency virus
(HIV) acquisition among pregnant and postnatal
women in Malawi8.
Changes inthevaginal microbialecosystem that
characterize bacterial vaginosis involve over-
growth of Gardnerella vaginalis, Bacteroides spp.,
Mobiluncusspp.and genital mycoplasmas, as well as
a reduction in Lactobacillus spp.9,10. Normal
lactobacillus-dominant vaginal flora provide rela-
tive protection against genital pathogens by pro-
ducing hydrogen peroxide (H2O2) and
bacteriocins, and by maintaining a low vaginal
pH11,12. The loss of these protective factors has
been hypothesized to increase the risk of HIV
acquisition in women with bacterial vaginosis. A
cross-sectional study in Thailand of commercial
sex workers attending a sexually transmitted
disease (STD) clinic found that HIV infection was
correlated with abnormal vaginal flora as well as
clinical bacterial vaginosis13. Similarly, a study in
Uganda found an association between HIV infec-
tion and bacterial vaginosis diagnosed by Gram’s
stain among women aged < 40 years14. More
recently, a prospective study among pregnant and
postnatal women in Malawi reported an increased
risk of HIV acquisition among women with
bacterial vaginosis8.
To determine whether prevalence of bacterial
vaginosis differs by HIV status in a high-risk US
population, we studied HIV-infected and un-
infected women participating in the HIV Epide-
miology Research (HER) Study, which included
sites in the Bronx, NY, Baltimore, MD, Detroit,
MI and Providence, RI.
METHODS
Study population
Between April 1993 and January 1995 we
recruited 1310 women to participate in the HER
Study; eligibility requirements included being
aged 16–55 years and having either a history of
injection drug use since 1985 or sexual risk
behaviors (e.g. > 5 sexual partners, trading sex for
drugs or money, or sex with a male injection drug
user or a man known or suspected to have HIV).
HIV-positive women were only accepted if they
did nothave an autoimmune deficiency syndrome
(AlDS)-defining clinical diagnosis15. As described
elsewhere16, women were recruited from health-
care settings, drug treatment programs and social
service organizations, and by word of mouth. The
study was approved by the institutional review
boards of each of the participating medical centers
and the Centers for Disease Control and Preven-
tion (CDC).
After informed consent was obtained, particip-
ants were administered a standardized face-to-face
interview to obtain medical, obstetric and
gynecologic histories, details of past and current
druguse and sexual behaviors, and information on
selected demographic and psychosocial factors.
Following the interview, all women received a
standardized physical examination and gave blood
for HIV testing (enzyme-linked immunosorbent
assay (ELISA) with confirmatory Western blot),
immunophenotyping, syphilis serology and other
laboratory tests.
Gynecologic examination
Allwomenunderwentastandardizedpelvic exam-
ination for diagnosis of gynecologic infection,
which included an endocervical culture for
Neisseria gonorrhoeae, a culture and direct fluores-
centantibodytest forChlamydia trachomatis, a vagi-
nal and anal culture for candida, and wet mounts
(saline and potassium hydroxide) for Trichomonas
vaginalis, clue cells and yeast. Vaginal pH was
measured using indicator strips (Baxter S/P,
Glendale, CA), and a whiff-amine test was per-
formed by adding a drop of 10% potassium
hydroxide to vaginal fluids and noting the release
of a fishy odor. Signs and symptoms of vaginal
infection at the time of physical examination were
noted. A swab of the posterior vaginal fornix was
used to prepare a smear that was air dried and fixed
in methanol, then shipped to a central laboratory
(Detroit Medical Center University Laboratories,
Detroit, MI) for Gram’s staining. Gram’s stain
slides were read by a single technologist who
was unaware of the clinical or HIV status of
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fication), slides wereexamined forthelactobacillus
morphotypes, Gardnerella and Bacteroides spp.
morphotypes (small Gram-negative to -variable
rods) and Mobiluncus spp. morphotypes. Each of
the three morphotypeswas quantitated and scored
as described by Nugent and colleagues17. For the
lactobacillus morphotypes and Gardnerella and
Bacteroides spp. morphotypes, the scores ranged
from 0 to 4; for the Mobiluncus spp. morphotypes
the score ranged from 0 to 2. The Gardnerella,
Bacteroides and Mobiluncus spp. morphotypes were
scored by giving those with the highest number of
organisms the highest score. For the lactobacillus
morphotypes the scoring was inversely related to
the number of organisms present; those with the
highest numbers of organisms received the lowest
score. The scores from each of the three
morphotypeswereaddedtogethertoget arangeof
possible scores from 0 to 10. A random sample
(n = 10) of Gram’s stain slides were read by an
independent investigator (Carol Spiegel, Univer-
sity ofWisconsin, Madison,WI)with 100% agree-
ment between the two readers.
Definitions
The Gram’s stain definition of bacterial vaginosis
was used as the primary outcome for this analysis.
The Gram’s stain diagnosis was made according to
the morphotype scoring system described above
and developed by Nugent and colleagues17: a score
of 0–3 was considered normal, 4–6was considered
intermediate and 7–10 was defined as bacterial
vaginosis. In addition, a clinical diagnosis was
defined using modified Amsel criteria18. The
clinical diagnosis of bacterial vaginosis required
that three of four conditions be present: vaginal
pH > 4.7, abnormal vaginal discharge, positive
whiff-aminetestoranycluecellsonmicroscopy.
Women with clinically diagnosed bacterial
vaginosis were offered standard antibiotic
therapy19 at the time of examination.
Statistical analysis
Analyses were conducted on data for the 1288
women (98.3% of the study group) who under-
went a complete gynecologic examination. To
investigate the correlates of bacterial vaginosis,
separate analyses were conducted comparing
womenbyGram’sstain result (score of7–10versus
0–6) and clinical diagnosis (yes, no). The c2 or
Fisher’s exact test was used to compare propor-
tions, and Student’s t-test to compare means
between groups.TheWilcoxonrank-sumtest was
employed forvariables that were notnormally dis-
tributed. Multiple logistic regression was used to
identify correlates of bacterial vaginosis. Variables
related to the study design were forced into all
models, since their distributions were manipulated
in the enrollment process. These included type of
risk behavior (sexual or injected drug use), HIV
status and the HER Study enrollment sites.
Variables screened for possible inclusion in the
multivariate models included covariates shown in
previous studies to be associated with bacterial
vaginosis or with HIV serostatus. In screening
variables for inclusion in an initial multivariate
model, models were fitted containing the study
design variables and the variable being evaluated.
Variables that exhibited at least moderate associa-
tion (p < 0.20) with the outcome in the presence
of these design variables were retained. Hence,
factors included in the initial models were those
related to the study design and those found to be
associated with bacterial vaginosis in the screening
process. First, multivariate models containingonly
main effects were fitted. Two-way interaction
terms comprising HIV status and each variable
retained in the main-effects-only model were sub-
sequently examined. Variables retained in the final
multivariate models included the study design
variables, significant interaction terms (and the
main effects that constituted them), main effects
that attained statistical significance and variables
whose exclusion meaningfully altered the adjusted
odds ratio of any other variables retained in the
model. In arriving at a final model, likelihood
ratio tests were used to assess the significance of
model terms and regression diagnostics were
examined20–23. Because the high prevalence of
bacterial vaginosis in the study population raised
concerns that the odds ratio may not accurately
approximate the relative risk, we calculated
standardized prevalence ratios and associated 95%
confidence intervals for the final Gram’s stain
bacterial vaginosis main-effects-only model using
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These methods were modified to accommodate
multilevel exposures based on a conversation with
Dr Rhodes. The marginal prediction method was
used with the HER Study cohort serving as the
standard population. All analyses were carried out
using Statistical Analysis System (SAS) software25.
RESULTS
Of the 1288 women in our analysis, 854 were
HIV-positive and 434 were HIV-negative. The
median age of the women was 35 years; 58% were
black, 24% were white and 16% were Hispanic.
Over two-thirds (72%) had monthly household
incomes less than $1000, 43% had less than a
high-school education and only 19% were
employed at enrollment. Most (76%) were
cigarette smokers and few were currently using
hormonalcontraceptives(5%) orspermicidal vagi-
nal products (4%). None of these characteristics
differed substantially according to HIV status. By
design, about half (51%) of the women had a
history of injection drug use since 1985, and the
remainder (49%) reported only sexual risk factors
for HIV; these proportions were similar in the
HIV-positive and HIV-negative groups.
Overall, 46% (592/1281) of women showed
bacterial vaginosis by Gram’s stain and 35%
(441/1268) met clinical criteria for bacterial
vaginosis. In the unadjusted analyses, the preva-
lence of bacterial vaginosis by Gram’s stain or by
clinical diagnosis did not differ significantly
according to HIV status (Table 1). In addition,
there were no significant differences by Gram’s
stain in either the presence of abnormal vaginal
flora (score 4–6) or the type of organisms (lacto-
bacillus morphotypes, Gardnerella and Bacteroides
spp. morphotypes, Mobiluncus spp. morphotypes)
present.
Comparison by HIV status of the 592 women
diagnosed with bacterial vaginosis by Gram’s stain
revealed similarities on numerous measures,
includingself-reportedabnormalvaginal discharge
and presence of T. vaginalis (Table 2).
In the multivariate analysis (Table 3), compar-
ing women with a diagnosis of bacterial vaginosis
(score 7–10) by Gram’s stain with those having
intermediate or normal vaginal flora (scores 0–6),
HIV status was significantly associated with a posi-
tive diagnosis of bacterial vaginosis (adjusted odds
ratio (OR) 1.31; 95% confidence interval (CI)
1.01–1.70). When an adjusted odds ratio was
calculated by comparing women with a diagnosis
of bacterial vaginosis (score 7–10) with those with
normal vaginal flora (score 0–3), the magnitude of
the association of HIV status with bacterial
vaginosis was slightly greater; however, the confi-
dence interval included 1.0 (adjusted OR 1.35;
95% CI 1.00–1.82: full model not shown).
Other covariates shown in the main multi-
variate model (Table 3) that were positively asso-
ciated with prevalent bacterial vaginosis by Gram’s
stain include sex with a female within the last
6 months, number of male sexual partners in
the last 6 months, sperm present on Gram’s
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HIV+ (n = 854) HIV (n = 434)
n % n % p value
Gram’s stain (score)*
Bacterial vaginosis (7–10)†
Intermediate vaginal flora (4–6)†
Normal vaginal flora (0–3)†
Bacterial vaginosis, clinical‡
Type of organisms by Gram’s stain (> 6 per field)
Lactobacillus morphotypes
Gardnerella and Bacteroides spp. morphotypes
Mobiluncus spp. morphotypes
402
157
293
293
325
533
87
47
18
34
34
38
63
10
190
77
162
148
173
250
39
44
18
38
34
40
58
9
0.36
0.89
0.26
0.93
0.49
0.15
0.59
*For bacterial vaginosis by Gram’s stain, there are seven missing values : five HIV and two HIV+;
†scores on Gram’s stain according to
system of Nugent and colleagues
17;
‡for clinically diagnosed bacterial vaginosis, there are 20 missing values: five HIV and 15 HIV+
Table 1 Prevalence of bacterial vaginosis and abnormal vaginal flora by human immunodeficiency virus (HIV) statusstain, smoking cigarettes in the past 6 months,
T. vaginalis by culture or wet mount, condyloma
on the vulva, vagina or cervix, and black race.
Vaginal candida colonization by culture was nega-
tively associated with prevalent bacterial vaginosis
by Gram’s stain (adjusted OR 0.50; 95% CI
0.39–0.66).
A multivariate analysis comparing women with
a clinical diagnosis of bacterial vaginosis with those
without a clinical diagnosis was also performed
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HIV+ (n = 402) HIV (n = 190)
n % n % p value*
Bacterial vaginosis, clinical†
Vaginal pH (median)
Abnormal vaginal discharge
Self-report
On physical exam
Clue cells
Wet mount
Gram’s stain
Trichomonas vaginalis
236
5.3
106
185
236
345
78
60‡
26‡
46‡
61‡
86‡
20‡
120
5.3
41
82
117
168
32
64‡
22‡
43‡
64‡
88‡
17‡
0.35
0.37
0.24
0.61
0.64
0.46
0.47
*c
2 Test for all p values except for vaginal pH where Wilcoxon rank-sum test is used;
†by Amsel’s criteria;
‡sample size decreased due to
missing data
Table 2 Description of clinical characteristics of women diagnosed with bacterial vaginosis using Gram’s stain criteria
reported separately by human immunodeficiency virus (HIV) status
Bacterial vaginosis by Gram’s stain* Clinical bacterial vaginosis
Unadjusted OR†
(95% CI)
Adjusted OR
(95% CI)
Unadjusted OR†
(95% CI)
Adjusted OR
(95% CI)
HIV-seropositive
Sex with female in last 6 months
Number of male sex partners in last 6
months
None
1
2 or more
Black race
Sperm present on Gram’s stain
Smoked cigarettes in last 6 months
Vaginal candida colonization
Trichomonas vaginalis
Vulvar, vaginal or cervical condyloma
Menses within last 14 days
Ectopy present
1.12 (0.89–1.42)
1.74 (1.14–2.67)
Referent
1.36 (1.02–1.81)
1.79 (1.27–2.51)
1.64 (1.24–2.17)
2.31 (1.57–3.41)
1.43 (1.08–1.88)
0.55 (0.43–0.71)
2.28 (1.58–3.31)
1.58 (1.10–2.26)
—
—
1.31 (1.01–1.70)
1.82 (1.14–2.90)
Referent
1.39 (1.02–1.91)
1.73 (1.21–2.48)
1.57 (1.17–2.12)
2.28 (1.51–3.44)
1.35 (1.01–1.82)
0.50 (0.39–0.66)
2.17 (1.47–3.19)
1.61 (1.10–2.34)
—
—
1.01 (0.78–1.31)
1.51 (0.96–2.36)
Referent
1.36 (0.99–1.88)
2.12 (1.46–3.08)
2.24 (1.64–3.06)
—
2.02 (1.47–2.79)
0.76 (0.58–0.99)
3.59 (2.45–5.25)
—
1.36 (1.06–1.75)
1.48 (0.99–2.21)
1.16 (0.87–1.55)
1.70 (1.04–2.78)
Referent
1.41 (0.99–2.00)
2.07 (1.40–3.08)
2.11 (1.51–2.93)
—
1.67 (1.20–2.35)
0.72 (0.54–0.96)
3.36 (2.26–4.99)
—
1.30 (0.99–1.70)
1.58 (1.04–2.40)
*Bacterial vaginosis by Gram’s stain defined as Gram score of 7–10 compared with referent group, 0–6;
†adjusted only by study design
variables: site, risk cohort and human immunodeficiency virus (HIV) status; OR, odds ratio; CI, confidence interval
Table 3 Unadjusted and adjusted risks of bacterial vaginosis diagnosed by Gram’s stain criteria or by clinical criteria
(Table 3). The unadjusted and adjusted oddsratios
were all in a similar direction to those in the
multivariate analysis using Gram’s stain for diag-
nosis. However, the associations with some
covariates did not reach statistical significance,
most notably the association of HIV seropositivity
(adjusted OR 1.16; 95% CI 0.87–1.55).
The association of the racial covariate was
explored in more detail. A model was con-
structed that included as covariates additionalmeasurements of socioeconomic status collected
for this study, including birth outside the United
States, not residing in own home or apartment, no
current employment, currently receiving public
assistance and total monthly household income of
< $1000.Inthismodeltherelationshipofbacterial
vaginosis by Gram’s stain and black race was not
substantially altered (adjusted OR 1.70; 95% CI
1.23–2.35: full model not shown).
For the main multivariate model, significant
interaction was foundbetween HIV serostatus and
vaginalcandidacolonization.Amongwomenwith
a positive candida culture, there was a significant
association of bacterial vaginosis by Gram’s stain
with HIV seropositivity (adjusted OR 2.85; 95%
CI 1.58–5.13). Among women with a negative
candida culture, there was no significant associa-
tion with HIV seropositivity (adjusted OR 1.05;
95%CI0.78–1.42),althoughtheassociation wasin
the same direction.
In a multivariate model restricted to HIV-
positive women (Table 4), antiretroviral drug use
was protective against bacterial vaginosis by
Gram’s stain (adjusted OR 0.54; 95% CI
0.38–0.77). There was no significant association of
CD4groupwithbacterialvaginosisinthismodel.
DISCUSSION
In this cross-sectional analysis of women with or at
risk for HIV infection, we found an increased risk
of bacterial vaginosis diagnosed by Gram’s stain
among women with HIV infection (adjusted OR
1.31; 95% CI 1.01–1.70). These findings, consis-
tent with two previous reports from Thailand and
Uganda13,14, are among the first reported for US
women being studied at other than clinical visits.
AmongwomenwithHIV,alowerCD4countwas
associated with an increased risk of bacterial
vaginosis, althoughthis association was notsignifi-
cant. Current antiretroviral use, however, was
associated with a decreased prevalence of bacterial
vaginosis.
The prevalence of bacterial vaginosis in this
group of women with or at risk for HIV infection
was very high, particularly as specimens were
obtained during pre-scheduled study visits that
were not symptom driven. Almost half (46%) the
women had bacterial vaginosis by Gram’s stain.
These high rates of bacterial vaginosis are similar
to findings in three studies of women attending
sexually transmitted disease clinics (range
12–61%)26–28, butare generally higher than reports
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Bacterial vaginosis by Gram’s stain*
Unadjusted OR† (95% CI) Adjusted OR (95% CI)
CD4 group
> 500
200–500
< 200
Current antiretroviral use
Sex with female in last 6 months
Number of male sex partners in last 6 months
None
1
2 or more
Black race
Sperm present on Gram’s stain
Smoked cigarettes in last 6 months
Vaginal candida colonization
Trichomonas vaginalis
Vulvar, vaginal or cervical condyloma
Referent
1.06 (0.78–1.45)
0.95 (0.63–1.44)
0.56 (0.41–0.75)
2.46 (1.36–4.46)
Referent
1.39 (1.00–1.94)
2.08 (1.36–3.18)
1.61 (1.14–2.29)
2.53 (1.54–4.14)
1.41 (1.01–1.96)
0.69 (0.52–0.92)
2.42 (1.54–3.81)
1.52 (1.02–2.26)
Referent
1.33 (0.93–1.91)
1.47 (0.92–2.35)
0.54 (0.38–0.77)
2.42 (1.26–4.63)
Referent
1.41 (0.98–2.04)
1.98 (1.25–3.14)
1.40 (0.96–2.04)
2.43 (1.43–4.14)
1.46 (1.01–2.10)
0.59 (0.43–0.81)
2.18 (1.35–3.52)
1.49 (0.97–2.28)
*Bacterial vaginosis by Gram’s stain defined as Gram score of 7–10 compared with referent group, 0–6;
†adjusted only by study design
variables: site and risk cohort; OR, odds ratio; CI, confidence interval
Table 4 Unadjusted and adjusted risks of bacterial vaginosis diagnosed by Gram’s stain criteria among human immu-
nodeficiency virus (HIV)-positive womenfor pregnant women (range 10–32%)3,29,30 and
above those for college students (range
4–23%)28,31. As has been reported in other
studies3,9,28, most bacterial vaginosis was asymp-
tomatic in this population, with less than one-
quarter (24.8%) of women reporting abnormal
vaginal discharge.
We choseto define bacterial vaginosis primarily
by Gram’s stain using the criteria of Nugent and
colleagues17, since it is generally thought to be
more reliable than wet mount32 and has been used
in a number of recent studies33,34. A smaller per-
centage of women (34%) met the clinical criteria
for bacterial vaginosis, compared with the Gram’s
stain diagnosis. The positive predictive value of
clinical diagnosis compared with Gram’s stain was
similar for HIV-positive and HIV-negative
women: 80.8% and 81.6%, respectively.
As in previous reports35,36, we found that
candida was protective against bacterial vaginosis.
Because there was significant interaction between
HIV serostatus and vaginal candida colonization,
we explored this relationship further. We found
that the association of HIV seropositivity with
bacterial vaginosis was significant among women
with a positive candida culture and not significant
(although in the same direction) among women
with a negative candida culture. Since more
HIV-infected women have candida, and since a
positive candida culture is somewhat protective
against bacterial vaginosis, this explains inpartwhy
the unadjusted odds ratio for HIV-seropositivity
was not significant and the adjusted odds ratio was
significant. It has been suggested that the over-
growth of anaerobic bacteria and increased pH
associated with bacterial vaginosis infection may
inhibit the growth of candida36.
In addition to candida, several other correlates
of bacterial vaginosis were identified in this study.
Consistent with several previous reports3,4, we
foundthat women who were positive for bacterial
vaginosis were more likely to be of black race.
Becauserace may beamarkerformanyunderlying
social, economic, cultural and behavioral factors37,
we attempted to control for as many of these
factors as we were able to measure in this study.
When we includedin themultivariate modelall of
the socioeconomic factors we collected, the
relationship between race and bacterial vaginosis
was not substantially altered, suggesting that race
may be a marker for an underlying factor that we
were not able to measure. Alternatively, race may
be a marker for the prevalence of bacterial
vaginosis in a particular community.
In this study, characteristics significantly related
to the presence of bacterial vaginosis included
having sex with a female within the last 6 months,
having more male sex partners in the last 6
months,having sperm present on theGram’s stain,
smoking cigarettes within the last 6 months,
having T. vaginalis and having genital condylo-
mata. Most of these covariates are related to more
frequent sexual activity, and a similar relationship
with numberof male partnerswas foundin a study
from Malawi. Additionally, the Malawi study also
reported increased prevalence of bacterial
vaginosis when T. vaginalis was present. The
relationship with having had sex with a female is
consistent with some evidence that female-to-
female transmission of bacterial vaginosis
occurs. In a small study of 21 lesbian couples, 72%
of partners of women with bacterial vaginosis also
had bacterial vaginosis, compared with only 10%
of partners of those without bacterial vaginosis38.
The limitations of this study should be taken
into accountwhen interpreting the results. Oneof
the goals of the HER study was to assess the effects
of HIV on gynecologic infection independent
of other risk factors such as drug use or sexual
behaviors; therefore, by design, all HIV-
uninfected HER study participants were at
increased risk for HIV and not necessarily repre-
sentative of all women without HIV. Thus,
generalizability of the results of this study to the
general population may be limited. In addition,
this analysis was cross-sectional, and therefore
cannot evaluate the incidence or persistence of
bacterial vaginosis.
In contrast to prior studies in which evaluations
were performed at clinical visits, this study evalu-
ated women at scheduled research visits, thereby
minimizing the potential biases associated with
symptom-driven evaluations. In addition, there
was multiple ascertainment of the diagnosis of
bacterial vaginosis (Gram’s stain and clinical cri-
teria) in this study, with consistency of results.
Given our finding that HIV-infected women
are more likely than uninfected women to have
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examine more closely this association longitudi-
nally, to determine whetherHIV-infected women
have a higher incidence of infection or whether
they have more persistent infections, or both.This
association may have important implications in
terms of treatment of bacterial vaginosis and pre-
vention of HIV acquisition.
ACKNOWLEDGEMENTS
Wethankallofthewomenwhoparticipated inthe
HER Study,thestudystaff andKarenManningfor
herassistance inthepreparationofthismanuscript.
Members of the HER Study Group
The HER Study group consists of the authors and
Ellie Schoenbaum, MD, Julia Arnsten, MD,
MPH, Penelope Demas, PhD, and Andrea
Howard, MD, MSc, from Montefiore Medical
Center and the Albert Einstein College of
Medicine; Suzanne Ohmit, DrPH, Michael Long
PhD, Wayne Lancaster PhD, and Jose Vazquez,
MD, from the Wayne State University School of
Medicine; Anne Rompalo, MD, David Vlahov,
PhD and David Celentano, PhD, from the Johns
Hopkins University School of Medicine; Charles
Carpenter, MD, Timothy Flanigan, MD, Joseph
Hogan, ScD, Valerie Stone, MD, Karen Tashima,
MD, and Josiah Rich, MD, from the Brown
University School of Medicine; Lytt I. Gardner,
PhD, Chad Heilig, PhD, Janet S. Moore, PhD,
Ruby M. Phelps, BS, and Dawn K. Smith, MD,
MPH, from the Centers for Disease Control and
Prevention; and Katherine Davenny, MPH, from
the National Institute of Drug Abuse.
REFERENCES
1. Gibbs RS. Chorioamnionitis and bacterial
vaginosis. Am J Obstet Gynecol 1993;169:460–2
2. Hauth JC, Goldenberg RL, Andrews WW, et al.
Reduced incidence of preterm delivery with
metronidazole and erythromycin in women with
bacterialvaginosis.NEnglJMed1995;333:1732–6
3. Hillier SL, Nugent RP, Eschenbach DA, et al.
Association between bacterial vaginosis and
preterm delivery of a low-birth-weightinfant.The
Vaginal Infections and Prematurity Study Group.
N Engl J Med 1995;333:1737–42
4. Meis PJ, Goldenberg RL, Mercer B, et al. The
preterm prediction study: significance of vaginal
infections. National Institute of Child Health and
Human Development Maternal–Fetal Medicine
Units Network. Am J Obstet Gynecol 1995;173:
1231–5
5. Larsson PG, Platz-Christensen JJ, Thejls H, et al.
Incidence of pelvic inflammatory disease after
first-trimester legalabortionin women with bacte-
rial vaginosis after treatment with metronidazole: a
double-blind, randomized study. Am J Obstet
Gynecol 1992;166:100–3
6. Padian NS, Washington AE. Pelvic inflammatory
disease. A brief overview. Ann Epidemiol 1994;4:
128–32
7. Sweet RL. Role of bacterial vaginosis in pelvic
inflammatory disease. Clin Infect Dis 1995;20
(Suppl 2):S271–5
8. Taha TE, Hoover DR, Dallabetta GA, et al. Bac-
terial vaginosis and disturbances of vaginal flora:
association with increased acquisition of HIV.
AIDS 1998;12:1699–706
9. Sobel JD. Vaginitis in adultwomen.Obstet Gynecol
Clin North Am 1990;17:851–79
10. Hillier SL. Diagnostic microbiology of bacterial
vaginosis. Am J Obstet Gynecol 1993;169:455–9
11. Hillier SL, Krohn MA, Rabe LK, et al. The normal
vaginal flora, H2O2-producing lactobacilli, and
bacterial vaginosis in pregnant women. Clin Infect
Dis 1993;16 (Suppl 4):S273–81
12. Klebanoff SJ. Inactivation of human immuno-
deficiency virus type 1 by the amine oxidase–
peroxidasesystem.JClinMicrobiol1995;33:2054–7
13. Cohen CR, Duerr A, Pruithithada N, et al. Bac-
terial vaginosis and HIV seroprevalence among
female commercial sex workers in Chiang Mai,
Thailand. AIDS 1995;9:1093–7
14. Sewankambo N, Gray RH, Wawer MJ, et al.
HIV-1 infection associated with abnormal vaginal
flora morphology and bacterial vaginosis. Lancet
1997;350:546–50
15. Centers for Disease Control and Prevention. 1993
Revised classification systemforHIV infection and
expanded surveillance case definition for AIDS
among adolescents and adults. Morbid Mortal
Weekly Rep 1992;41(RR-17):1–19
Bacterial vaginosis and HIV Warren et al.
140 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY16. Smith DK, Warren D,VlahovD, et al. The design,
participants, and selected early findings of the HIV
Epidemiology Research (HER) Study: a prospec-
tive cohortstudyoftheimpactofHIVinfection on
the health of American women. Am J Epidemiol
1997;146:459–69
17. Nugent RP, Krohn A, Hillier SL. Reliability of
diagnosing bacterial vaginosis is improved by a
standardized method of Gram stain interpretation.
J Clin Microbiol 1991;29:297–301
18. Amsel RM, Totten PA, Spiegal CA, et al. Non-
specific vaginitis: diagnostic criteria and microbial
andepidemiologicassociations.Am J Med1983;74:
14–22
19. Centers for Disease Control and Prevention. 1993
Sexually transmitted diseases treatment guidelines.
MorbidMortalWeeklyRep1993;42(RR-14):68–70
20. Belsley DA, Kuh E, Welsch RE. Regression Diag-
nostics. New York: John Wiley & Sons, 1980
21. Davis CE, Hyde JE, Bangdiwala SI, Nelson JJ. An
exampleofdependenciesamongvariablesinacon-
ditional logistic regression. In Moolgavkar SH,
Prentice RL, eds. Modern Statistical Methods in
Chronic Disease Epidemiology. New York: John
Wiley & Sons, 1986:140–7
22. HosmerDW, Lemeshow S. Applied Logistic Regres-
sion. New York: John Wiley & Sons, 1989:140–5
23. Pregibon D. Logistic regression diagnostics. Ann
Stat 1981;9:705–24
24. Flanders WD, Rhodes PH. Large sample confi-
dence intervals for regression standardized risks,
risk ratios, and risk differences. J Chron Dis
1987;40:697–704
25. SAS Institute Inc. SAS/STAT Software: Changes
and Enhancements through Release 6.12. Cary, NC:
SAS Institute Inc., 1997:1–1167
26. CentersforDiseaseControl.Nonreportedsexually
transmissible disease – United States. Morbid Mortal
Weekly Rep 1979:28:61–3
27. Embree J, Caliando JJ, McCormack WM. Non-
specific vaginitis among women attending a
sexually transmitted diseases clinic. Sex Transm Dis
1984;11:81–4
28. Eschenbach DA, Hillier S, Critchlow C, et al.
Diagnosis and clinical manifestations of bacterial
vaginosis. Am J Obstet Gynecol 1988;158:819–28
29. Gravett MG, Nelson HP, DeRouen T, et al. Inde-
pendent associations of bacterial vaginosis and
Chlamydia trachomatis infection with adverse preg-
nancy outcome. J Am Med Assoc 1986;225:
1899–903
30. Minkoff H, Grunebaum AN, Schwarz RH, et al.
Risk factors forprematurity and prematurerupture
of membranes:prospective study of vaginal flora in
labor. Am J Obstet Gynecol 1984;150:965–72
31. Spiegel CA, Amsel R, Eschenbach D, et al. Anaer-
obic bacteria in nonspecific vaginitis. N Engl J Med
1980;303:601–7
32. Sobel JD. Vaginitis. N Engl J Med 1997;337:
1896–903
33. Carey JC, Klebanoff MA, Hauth JC, et al.
Metronidazole to prevent preterm delivery in
pregnant women with asymptomatic bacterial
vaginosis. N Engl J Med 2000;342:534–9
34. Royce RA, Thorp J,GranadosJL, Savitz DA.Bac-
terial vaginosis associated with HIV infection in
pregnant women from North Carolina. J AIDS
1999;20:382–6
35. Taha TE, Gray RH, Kumwenda NI, et al. HIV
infection and disturbances of vaginal flora during
pregnancy. J AIDS 1999:20:52–9
36. Martin HL, Richardson BA, Nyange PM, et al.
Vaginal lactobacilli, microbial flora, and risk of
human immunodeficiency virus type 1 and sexu-
ally transmitted disease acquistion. J Infect Dis
1999;180:1863–8
37. Centers for Disease Control. Morbid Mortal Weekly
Rep 1993;42(RR-10):
38. Berger BJ, Kolton S, Zenilman JM, et al. Bacterial
vaginosis in lesbians: a sexually transmitted disease.
Clin Infect Dis 1995;21:1402–5
RECEIVED 4/23/01; ACCEPTED 5/28/01
Bacterial vaginosis and HIV Warren et al.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 141